OncoSec Medical Inc (NASDAQ:ONCS) issued positive updated long-term follow-up report from its Phase II OMS I-102 combination trial of pembrolizumab and ImmunoPulse® IL-12 in patients doubtful to respond to anti-PD-1 treatment.
The updated report will be showcased in an oral poster presentation by Dr. Alain Alagzi at the SITC Annual Meeting on November 10, 2017. The event will comprise a discussion and presentation of updated clinical report for the firm’s ImmunoPulse IL-12 program, showcasing the international, registration-directed PISCES/KEYNOTE-695 study.
The details
The updated correlative and clinical immune-focused biomarker data exhibited a 57% progression free survival rate at 15 months with 100% duration of response and median progression free survival not yet reached. Building upon earlier issued report of a best overall response rate of 50%, the updated data further show that the combination of these treatments can prime a coordinated adaptive and innate immune response, and firmly indicates a synergistic association with anti-PD-1.
The latest data further show that this combination plan can reshape the tumor microenvironment, resulting in a systemic anti-tumor and robust intratumoral response converting “cold” tumors to “hot,” probably improving clinical results in patients expected to not respond to anti-PD-1 treatment.
Dr. Alain Algazi, the Lead Trial Investigator, expressed that overall, the Phase II study data, counting progression free survival beyond 2 years in numerous patients, best overall response rate, tolerability of the combination and duration of response, offer a consistent and strong theme across numerous endpoints, underlining the promise of pembrolizumab and ImmunoPulse IL-12 as a viable treatment alternative for people diagnosed with metastatic melanoma.
Dan O’Connor, the CEO of OncoSec, expressed that the impressive PFS tolerability and benefit seen with ImmunoPulse IL-12 and pembrolizumab is the initial demonstrating efficacy in a foreseen PD-1 non-responder population and demonstrates that the combination exhibits a potentially vital addition to the treatment setting for people with metastatic melanoma who are progressing or have progressed on anti-PD-1 therapy.
